Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib

Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib

Understanding the genetic mechanisms of sensitivity to targeted anticancer therapies may improve patient selection, response to therapy, and rational treatment designs. One approach to increase this understanding involves detailed studies of exceptional responders: rare patients with unexpected exqu...

Full description

Bibliographic Details
Main Authors: Wagle, N., Grabiner, Brian C., Van Allen, E. M., Hodis, Eran, Jacobus, S., Supko, J. G., Stewart, M., Choueiri, T. K., Gandhi, L., Cleary, J. M., Elfiky, A. A., Taplin, M. E., Stack, E. C., Signoretti, S., Loda, Massimo, Shapiro, G. I., Gabriel, Stacey B., Kantoff, Philip W., Garraway, Levi A., Rosenberg, J. E., Sabatini, David, Lander, Eric Steven
Other Authors: Massachusetts Institute of Technology. Department of Biology
Format: Article
Language:en_US
Published: American Association for Cancer Research 2015
Online Access:http://hdl.handle.net/1721.1/96675
https://orcid.org/0000-0002-1446-7256

Internet

http://hdl.handle.net/1721.1/96675
https://orcid.org/0000-0002-1446-7256

Similar Items